Medipure Pharmaceuticals is a biopharmaceutical incubator committed to discovering, researching and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms. Medipure's approach is to develop proprietary drugs with minimized side effects and maximized benefits for the affordable treatment of specific ailments.
Our core products target specific disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis and dermatology. Medipure's intellectual property includes a robust and healthy patent-protected drug pipeline. Our core strengths include a world class research and development team combined with a formidable management team and global partnerships with research insititutions and the private sector.
With Medipure's knowledge and expertise in the regulatory process, we plan to have our first derivative product prepared for market entry in 2018.
Sign up to receive news regarding our company.